403 related articles for article (PubMed ID: 28490565)
21. The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial.
Kato K; Suzuki K; Aoki C; Sagara M; Niitani T; Wakamatsu S; Yanagi K; Aso Y
Expert Opin Pharmacother; 2017 Jun; 18(8):743-751. PubMed ID: 28426260
[TBL] [Abstract][Full Text] [Related]
22. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
Ridderstråle M; Andersen KR; Zeller C; Kim G; Woerle HJ; Broedl UC;
Lancet Diabetes Endocrinol; 2014 Sep; 2(9):691-700. PubMed ID: 24948511
[TBL] [Abstract][Full Text] [Related]
23. Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes.
Ohta A; Kato H; Ishii S; Sasaki Y; Nakamura Y; Nakagawa T; Nagai Y; Tanaka Y
Expert Opin Pharmacother; 2017 Oct; 18(14):1433-1438. PubMed ID: 28770629
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of a sodium-glucose co-transporter-2 inhibitor versus placebo as an add-on therapy for people with type 2 diabetes inadequately treated with metformin and a dipeptidyl peptidase-4 inhibitor: a systematic review and meta-analysis of randomised controlled trials.
De Buitléir C; O' Connor E; Satti MM; Shaw J; Liew A
Diabet Med; 2021 Feb; 38(2):e14409. PubMed ID: 32979231
[TBL] [Abstract][Full Text] [Related]
25. TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea-a MASTERMIND study protocol.
Angwin C; Jenkinson C; Jones A; Jennison C; Henley W; Farmer A; Sattar N; Holman RR; Pearson E; Shields B; Hattersley A;
BMJ Open; 2020 Dec; 10(12):e042784. PubMed ID: 33371044
[TBL] [Abstract][Full Text] [Related]
26. Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study.
Kameda R; Nomoto H; Cho KY; Kawata S; Omori K; Takeuchi J; Nagai S; Kurihara Y; Aoki S; Nakamura A; Atsumi T; Miyoshi H
BMJ Open; 2020 Feb; 10(2):e034883. PubMed ID: 32034028
[TBL] [Abstract][Full Text] [Related]
27. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.
Ji L; Han P; Liu Y; Yang G; Dieu Van NK; Vijapurkar U; Qiu R; Meininger G
Diabetes Obes Metab; 2015 Jan; 17(1):23-31. PubMed ID: 25175734
[TBL] [Abstract][Full Text] [Related]
28. A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin.
Seino Y; Kaku K; Kadowaki T; Okamoto T; Sato A; Shirakawa M; O'Neill EA; Engel SS; Kaufman KD
Diabetes Obes Metab; 2021 Jun; 23(6):1342-1350. PubMed ID: 33565686
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.
Kashiwagi A; Yoshida S; Nakamura I; Kazuta K; Ueyama E; Takahashi H; Satomi H; Kosakai Y; Kawamuki K
J Diabetes Investig; 2016 Jul; 7(4):544-54. PubMed ID: 27181576
[TBL] [Abstract][Full Text] [Related]
30. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics.
Osonoi T; Nakamoto S; Saito M; Tamasawa A; Ishida H; Osonoi Y
J Diabetes Investig; 2018 Mar; 9(2):341-353. PubMed ID: 28644562
[TBL] [Abstract][Full Text] [Related]
32. Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial.
Tanaka M; Yamakage H; Inoue T; Odori S; Kusakabe T; Shimatsu A; Satoh-Asahara N
Intern Med; 2020; 59(5):601-609. PubMed ID: 32115517
[TBL] [Abstract][Full Text] [Related]
33. Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes.
Bae J; Kim YE; Lee M; Lee YH; Lee BW; Cha BS; Kang ES
Yonsei Med J; 2022 Jun; 63(6):539-544. PubMed ID: 35619577
[TBL] [Abstract][Full Text] [Related]
34. The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials.
Storgaard H; Gluud LL; Christensen M; Knop FK; Vilsbøll T
BMJ Open; 2014; 4(8):e005378. PubMed ID: 25232561
[TBL] [Abstract][Full Text] [Related]
35. Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink.
Wilding J; Godec T; Khunti K; Pocock S; Fox R; Smeeth L; Clauson P; Fenici P; Hammar N; Medina J
BMC Med; 2018 Jul; 16(1):116. PubMed ID: 30008267
[TBL] [Abstract][Full Text] [Related]
36. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Kawalec P; Mikrut A; Łopuch S
Diabetes Metab Res Rev; 2014 May; 30(4):269-83. PubMed ID: 24829965
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice.
Tahara A; Takasu T
Endocr Res; 2020; 45(2):147-161. PubMed ID: 31955626
[No Abstract] [Full Text] [Related]
38. Two years with GIOIA 'Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes': A prospective, multicentre, quasi-experimental study on sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors in diabetes clinical practice.
Longo M; Caruso P; Scappaticcio L; Maiorino MI; Bellastella G; Capuano A; Esposito K; Giugliano D
Diabetes Obes Metab; 2024 Apr; 26(4):1492-1501. PubMed ID: 38234208
[TBL] [Abstract][Full Text] [Related]
39. A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus.
Shestakova MV; Wilding JPH; Wilpshaar W; Tretter R; Orlova VL; Verbovoy AF
Diabetes Res Clin Pract; 2018 Dec; 146():240-250. PubMed ID: 30391333
[TBL] [Abstract][Full Text] [Related]
40. A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study.
Kashiwagi A; Takahashi H; Ishikawa H; Yoshida S; Kazuta K; Utsuno A; Ueyama E
Diabetes Obes Metab; 2015 Feb; 17(2):152-60. PubMed ID: 25347938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]